

STROBE Statement—checklist of items that should be included in reports of observational studies

Prevalence and determinants of overweight/obesity among school-aged adolescents in the United Arab Emirates: A cross sectional study of private and public schools

| | Item No. | Recommendation | Page No. | Relevant text from manuscript |
|----------------------|----------|---|----------|---|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 1 | See title page and abstract Prevalence and determinants of overweight/obesity among school-aged adolescents in the United Arab Emirates: A cross sectional study of private and public schools |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2-3 | See abstract section |
| Introduction | | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 5-7 | See background section |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 7 | In this study, we explored the epidemiology of overweight and obesity in the total population and compared obesity figures between private and public schools. We also aimed to determine factors that contributed to overweight and obesity in participants including sociodemographic factors (sex, age, nationality, parents' employment and socioeconomic status); school type (public vs. private); and lifestyle factors (F/V consumption, physical activity levels). |
| Methods | | | | |
| Study design | 4 | Present key elements of study design early in the paper | 7 | We adopted a quantitative correlational design |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 7-8 | See subjects and methods |
| Participants | 6 | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | | |

| | | | | |
|------------------------------|----|--|--------------|--|
| | | <p><i>Case-control study</i>—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i>—Give the eligibility criteria, and the sources and methods of selection of participants</p> | 8 | |
| | | <p>(b) <i>Cohort study</i>—For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i>—For matched studies, give matching criteria and the number of controls per case</p> | Not relevant | |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 9-11 | See measurement section (page 9-10), also data analysis section (page 11) |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 9-10 | Full descriptions of all variables measured provided –under measurement section |
| Bias | 9 | Describe any efforts to address potential sources of bias | 8-9, 11 | <p>We used trained research assistants</p> <p>The same research team collected the data</p> <p>Random selection of school through cluster sampling</p> <p>Multivariate logistic regression (page 11)</p> |
| Study size | 10 | Explain how the study size was arrived at | 8 | See last paragraph of participants and samples |

Continued on next page

| | | | | |
|------------------------|-----|---|---|--|
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 11 | Data analysis section |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 11 | Data analysis section |
| | | (b) Describe any methods used to examine subgroups and interactions | | |
| | | (c) Explain how missing data were addressed | 11 | Results section, paragraph 1 Missing and incomplete data were eliminated from the analyses. |
| | | (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy | 11 | |
| | | (e) Describe any sensitivity analyses | NA | |
| Results | | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 11 | Results section, paragraph 1 |
| | | (b) Give reasons for non-participation at each stage | 11 | Results section, paragraph 1 |
| | | (c) Consider use of a flow diagram | Included as separate file (available online) | Figure 1 |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 11-12 | Participants' characteristics and obesity-related indices Table 1 |
| | | (b) Indicate number of participants with missing data for each variable of interest | NA | |
| | | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) | NA | |

| | | | | |
|--------------|-----|--|-------|-----------------|
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time | NA | |
| | | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure | NA | |
| | | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures | 11-17 | Results section |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 11-17 | Results section |
| | | (b) Report category boundaries when continuous variables were categorized | 11-17 | Results section |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | NA | |

Continued on next page

| | | | | |
|--------------------------|----|--|-------|---|
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | NA | |
| Discussion | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 16-20 | Discussion section |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 21 | See strengths limitation section |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 21 | See strengths limitation section |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 21 | See strengths limitation section |
| Other information | | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 21 | This research was funded by the University of Sharjah/Research Institute for Medical and Health Sciences\ Health Promotion Research Group (Grant number 150310) |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.